Dr. Dawn Bowdish and her PhD student Dessi Loukov collaborated with Dr. Monica Maly and Sara Karampatos (Rehabilitation Science) and found that monocytes were more activated and pro-inflammatory in women with osteoarthritis, and that elevated inflammation and body mass index were associated with increased monocyte activation. Further, the team found that women with osteoarthritis and more activated monocytes experienced worse pain than individuals with less activated monocytes. These findings highlight the importance of modulating inflammation and body mass to manage osteoarthritis and open up new avenues for therapeutic research.
Read the full publication in the Osteoarthritis Research Society International (OARSI) Journal
As featured in Eureka Alert: https://www.eurekalert.org/pub_releases/2017-11/mu-rul112717.php
Congratulations to Fiona Whelan (MSc, Bowdish lab; PhD student, Surette lab) for publishing the review article “A guide to bioinformatics for immunologists” in Frontiers Immunology. The idea of this article spawned from the research that Fiona conducted in the Bowdish lab on the elucidation of the evolutionary history and relationships between the members of the class A scavenger receptors, proteins required for host defense and homeostasis. During this time, Fiona used multiple bioinformatic techniques and tools to form hypotheses as to the function of one under-annotated member of this family, SCARA3. Even though most of these tools are easy-to-use and require little computational knowledge, Fiona and Dawn discovered through their interactions with other immunologists that these tools were being under utilized. Thus, they decided to write a review of how bioinformatic techniques can help the average immunologist in their quest for knowledge about the structure of their protein of interest, how to find SNPs that may correlate with disease phenotype, and how to conduct sequence alignments in order to find areas that are conserved across various genes.
This review article is written as a case study that follows Fiona’s research into SCARA3 that begins with obtaining the NCBI Reference FASTA sequence of the protein, predicting post-translational modifications, identifying conserved motifs, hypothesizing as to the structure of the protein, examining SCARA3’s transcriptomic profile in different immunological cell types, and analyzing any potential SNPs within the DNA sequence of SCARA3 that may correlate with disease. The article is written with the immunologist in mind and includes the use of only “point and click” tools that require no computational background whatsoever.
The laboratories of both Dr. Bowdish and Dr. Surette are always interested in undergraduate and graduate students interested in exploring the impact bioinformatics can have on immunological and microbiological research.
Bowdish lab associate member (technically she’s supervised by Dr. Mike Surette but we think of her as one of our own), Julie Kaiser, successfully defended her MSc thesis “Host responses to the Strepotococcus Milleri Group”. To see a photo of Julie in her post exam bliss/haze click here. Julie is moving on to a PhD at UWO in Dr. Dave Heinrichs lab. We’re sending Dave on of our best & brightest – we expect a thank you card any day now.
The lab of Dr. Dawn Bowdish at the McMaster University Immunology Research Centre (MIRC) has recently begun collaboration with the Vancouver-based pharmaceutical company Qu Biologics on preclinical studies investigating the role of macrophage dysfunction in chronic inflammation.
Qu Biologics has developed Site Specific Immunomodulators (SSIs), which aim to “reboot” the body’s innate immune system in targeted organs or tissues to reverse chronic inflammation.
“Macrophages are important cells of the innate immune system. There is growing evidence that macrophage dysfunction underlies many important common chronic diseases, including cancer and autoimmune disease,” said Dr. Hal Gunn, CEO of Qu Biologics. “This collaboration will be invaluable to assist in our understanding of the benefits of SSI therapy on macrophage function as it relates to chronic inflammation and immune dysfunction.” Dr. Gunn added.
The studies will test whether a lung-specific SSI therapy can restore normal lung and bone marrow-derived macrophage function using a variety of in vivo and in vitro assays.
Dr. Bowdish adds “This is an ambitious and exciting project that takes a fundamentally different approach to tackling the problem of chronic inflammation, which has been very resistant to therapeutic intervention. My team is thrilled to be working together on a problem that affects the lives of so many Canadians.” This work capitalizes on the resources and immunology expertise of the McMaster Immunology Research Centre and Dr. Bowdish’s research interests in how inflammation impairs macrophage function.
About Qu Biologics
Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to reboot the body’s immune system. SSIs are designed to stimulate an immune response in targeted organs or tissues to potentially reverse the chronic inflammation underlying many conditions including cancer and autoimmune disease. The company recently launched a Phase 1/2 clinical trial to research SSI therapy for the treatment of Crohn’s disease.
Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body’s immune response to chronic disease; and Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control in Canada and internationally. For more information, visit www.qubiologics.com and www.qucrohnstrial.com.
For more details and to see the original press release here:
Fan Fei (PhD candidate), under the supervision of Dr. Brian McCarry, and in conjunction with Bowdish lab undergraduate Keith Lee, studies age related changes in the inflammatory response from a metabolomics perspective. Funded by the Russell Bell Travel Scholarship award, she attended the 9th Annual conference of the Metabolomics Society. July 1-4, 2013, SECC Glasgow. She won the “Glasgow Polyomics & University of Strathclyde Young Scientist Award” for outstanding poster presentation of research in the field of metabolomics at the Metabolomic Conference 2013 in Glasgow Scotland for her work “Comprehensive Metabolomic Analysis Reveals Major Differences in the Macrophage Inflammatory Response Between Young and Aged Mice”. Way to go Fan!
The IIDR has awarded the Bowdish lab seed money to study the role of macrophages in host response to colonization by Streptococcus pneumoniae. S. pneumoniae infections can range from treatable (respiratory tract infections, otitis) to life-threatening (meningitis, sepsis). The introduction of the pneumococcal conjugate vaccine (PCV) has shifted the epidemiology of S. pneumoniae infections but not eliminated them. In humans, colonization of the upper respiratory tract is the initial step in pathogenesis. This is accompanied by a robust antibody response, which is generally believed to be required for clearance (and thus prevention of infection); however, data for this is not supported by clinical observations in which high levels of antibodies are not associated with clearance or in which immunodeficient patients susceptible to pneumococcal infections can produce robust anti-pneumococcal antibody responses while still being prone to recurrent systemic infections. The aim of this project is to assess the importance of macrophages in the recognition and clearance of S. pneumoniae in the upper respiratory tract. This work will be done in collaboration with Prof. Jeffrey Weiser at the University of Pennsylvania who is a world leader in the field of S. pneumoniae pathogenesis. Dawn will be travelling to his lab in July to learn from his lab members. The Bowdish lab is currently recruiting graduate students and post-docs who are interested in the host response to S. pneumoniae infection and colonization.